Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its third Process Qualification (“PQ”) run of
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor (“CBR”) platform technology, designed to program immune cells to
One of America’s Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept (“POC”) for its
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration (“FDA”) that the proposed pre-Investigational
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application.